Literature DB >> 12023032

Ro 31-6045, the inactive analogue of the protein kinase C inhibitor Ro 31-8220, blocks in vivo activation of p70(s6k)/p85(s6k): implications for the analysis of S6K signalling.

Nelly Marmy-Conus1, Katherine M Hannan, Richard B Pearson.   

Abstract

The mitogen-stimulated protein kinase p70(s6k)/p85(s6k) (S6K) plays an essential role in cell proliferation and growth, with inhibitors of the S6K signalling pathway showing promise as anti-tumour therapeutics. Here, we report that the bisindolylmaleimide derivative Ro 31-6045, previously reported to be inactive as a kinase inhibitor, inhibited S6K activity in vivo with an IC50=8 microM. Structure/function analysis using mutant forms of S6K indicates that Ro 31-6045 inhibition is independent of the upstream activator mTOR. Ro 31-6045 will prove useful in elucidating the complex activation mechanism of S6K and its independence from mTOR will allow confirmation of functional data obtained using the mTOR inhibitor rapamycin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12023032     DOI: 10.1016/s0014-5793(02)02738-2

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  10 in total

Review 1.  Resistance to insulin and kidney disease in the cardiorenal metabolic syndrome; role for angiotensin II.

Authors:  Ravi Nistala; Adam Whaley-Connell
Journal:  Mol Cell Endocrinol       Date:  2013-02-15       Impact factor: 4.102

2.  mTOR/p70S6K signaling distinguishes routine, maintenance-level autophagy from autophagic cell death during influenza A infection.

Authors:  Alireza Shirazian; Shawna Benjamin; Emmanuel Datan; Demetrius Matassov; Antonella Tinari; Walter Malorni; Richard A Lockshin; Adolfo Garcia-Sastre; Zahra Zakeri
Journal:  Virology       Date:  2014-02-05       Impact factor: 3.616

3.  Activation of S6K1 (p70 ribosomal protein S6 kinase 1) requires an initial calcium-dependent priming event involving formation of a high-molecular-mass signalling complex.

Authors:  Katherine M Hannan; George Thomas; Richard B Pearson
Journal:  Biochem J       Date:  2003-03-01       Impact factor: 3.857

Review 4.  Frontier of epilepsy research - mTOR signaling pathway.

Authors:  Chang Hoon Cho
Journal:  Exp Mol Med       Date:  2011-05-31       Impact factor: 8.718

5.  CCL2 is a negative regulator of AMP-activated protein kinase to sustain mTOR complex-1 activation, survivin expression, and cell survival in human prostate cancer PC3 cells.

Authors:  Hernan Roca; Zachary S Varsos; Kenneth J Pienta
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

6.  Identification of novel host-targeted compounds that protect from anthrax lethal toxin-induced cell death.

Authors:  Louise H Slater; Erik C Hett; Kevin Mark; Nicole M Chumbler; Deepa Patel; D Borden Lacy; R John Collier; Deborah T Hung
Journal:  ACS Chem Biol       Date:  2013-02-04       Impact factor: 5.100

Review 7.  Insulin Resistance in Kidney Disease: Is There a Distinct Role Separate from That of Diabetes or Obesity?

Authors:  Adam Whaley-Connell; James R Sowers
Journal:  Cardiorenal Med       Date:  2017-09-30       Impact factor: 2.041

8.  ER stress and autophagy dysfunction contribute to fatty liver in diabetic mice.

Authors:  Quan Zhang; Yan Li; Tingting Liang; Xuemian Lu; Chi Zhang; Xingkai Liu; Xin Jiang; Robert C Martin; Mingliang Cheng; Lu Cai
Journal:  Int J Biol Sci       Date:  2015-04-02       Impact factor: 6.580

9.  FMRP S499 is phosphorylated independent of mTORC1-S6K1 activity.

Authors:  Christopher M Bartley; Rachel A O'Keefe; Angélique Bordey
Journal:  PLoS One       Date:  2014-05-07       Impact factor: 3.240

10.  Characterization of an environmental DNA-derived gene cluster that encodes the bisindolylmaleimide methylarcyriarubin.

Authors:  Fang-Yuan Chang; Sean F Brady
Journal:  Chembiochem       Date:  2014-03-19       Impact factor: 3.164

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.